CD274 and breast carcinoma: In addition, Zhang et al. generated PD-L1-degrading iLYTACs with recombinant proteins fused to the insulin-like growth factor 2 gene and PD-L1 nanoantibodies, which were tested in MDA-MB-231 breast cancer cells.